Enwave Corporation Stock
€0.14
Your prediction
Enwave Corporation Stock
Pros and Cons of Enwave Corporation in the next few years
Pros
Cons
Performance of Enwave Corporation vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Enwave Corporation | -4.930% | -1.460% | -17.683% | -42.308% | -42.797% | -46.850% | -82.955% |
| Aurinia Pharmaceuticals Inc. | 5.170% | 0.451% | -2.517% | 88.914% | -0.817% | 50.960% | 12.128% |
| Spectral Medical Inc | -1.160% | 1.183% | 1.183% | 58.333% | 7.547% | 319.118% | 185.000% |
| Xenon Pharmaceuticals Inc. | 0.850% | 0.427% | 0.858% | 85.039% | 23.684% | 24.339% | - |
News
EnWave Reports 2026 First Quarter Consolidated Interim Financial Results
Vancouver, B.C., February 20th, 2026. EnWave Corporation (TSX-V:ENW | FSE:E4U) (“EnWave”, or the "Company") today reported the Company’s consolidated interim financial results for the first
EnWave Signs Royalty-Bearing License with Bowen Gumlu Grower’s Association of Australia
Vancouver, B.C., February 2nd, 2026, EnWave Corporation (TSX-V:ENW | FSE:E4U) (“EnWave”, or the "Company") today announced that the Company has signed a royalty-bearing commercial license
EnWave Reports 2025 Fourth Quarter and Annual 2025 Consolidated Financial Results
Vancouver, B.C., December 15th, 2025 / EnWave Corporation (TSX-V:ENW | FSE:E4U) (“EnWave”, or the "Company") today reported the Company’s consolidated interim financial results for the fourth

